0001013762-23-002838.txt : 20231010 0001013762-23-002838.hdr.sgml : 20231010 20231010161515 ACCESSION NUMBER: 0001013762-23-002838 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230929 FILED AS OF DATE: 20231010 DATE AS OF CHANGE: 20231010 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eureka Therapeutics, Inc. CENTRAL INDEX KEY: 0001386560 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40608 FILM NUMBER: 231318142 BUSINESS ADDRESS: STREET 1: 5858 HORTON ST STE 170 CITY: Emeryville STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 654-7045 MAIL ADDRESS: STREET 1: 5858 HORTON ST STE 170 CITY: Emeryville STATE: CA ZIP: 94608 FORMER NAME: FORMER CONFORMED NAME: Eureka Therapeutics Inc DATE OF NAME CHANGE: 20070112 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Estrella Immunopharma, Inc. CENTRAL INDEX KEY: 0001844417 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 861314502 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5858 HORTON STREET, SUITE 170 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: (510) 318-9098 MAIL ADDRESS: STREET 1: 5858 HORTON STREET, SUITE 170 CITY: EMERYVILLE STATE: CA ZIP: 94608 FORMER COMPANY: FORMER CONFORMED NAME: TradeUP Acquisition Corp. DATE OF NAME CHANGE: 20210204 3 1 ownership.xml X0206 3 2023-09-29 0 0001844417 Estrella Immunopharma, Inc. ESLA 0001386560 Eureka Therapeutics, Inc. 5858 HORTON STREET, SUITE 170 EMERYVILLE, CA 9460 0 0 1 0 Common Stock 25277831 D Exhibit List: Exhibit 24 - Power of Attorney. /s/ Emily Semon, as attorney-in-fact 2023-10-10 EX-24 2 ea186538ex24_estrella.htm POWER OF ATTORNEY

Exhibit 24

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby constitutes and appoints each of Michael Blankenship, Aaron Walker, Andrew Butler, Emily Semon, Robbie Oakes and Roman Koidl, or either of them acting singly and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

1. execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer or director or both or 10% or greater beneficial owner of Estrella Immunopharma, Inc. (the “Company”), Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules thereunder;

2. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the “SEC”) and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC; and

3. take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in- fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in- fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the undersigned has executed this Limited Power of Attorney as of this 3^rd day of October, 2023.

EUREKA THERAPEUTICS, INC.

By:	/s/ Cheng Liu
	Name:	Cheng Liu
	Title:	CEO